These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28398597)

  • 1. Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.
    Tran JQ; Hartung JP; Peach RJ; Boehm MF; Rosen H; Smith H; Brooks JL; Timony GA; Olson AD; Gujrathi S; Frohna PA
    J Clin Pharmacol; 2017 Aug; 57(8):988-996. PubMed ID: 28398597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.
    Tran JQ; Hartung JP; Tompkins CA; Frohna PA
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):634-640. PubMed ID: 29125718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA; Arnold DL; Comi G; Bar-Or A; Gujrathi S; Hartung JP; Cravets M; Olson A; Frohna PA; Selmaj KW;
    Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
    Sandborn WJ; Feagan BG; Wolf DC; D'Haens G; Vermeire S; Hanauer SB; Ghosh S; Smith H; Cravets M; Frohna PA; Aranda R; Gujrathi S; Olson A;
    N Engl J Med; 2016 May; 374(18):1754-62. PubMed ID: 27144850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.
    Tran JQ; Hartung JP; Olson AD; Mendzelevski B; Timony GA; Boehm MF; Peach RJ; Gujrathi S; Frohna PA
    Clin Pharmacol Drug Dev; 2018 Mar; 7(3):263-276. PubMed ID: 28783871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers.
    Xu J; Gray F; Henderson A; Hicks K; Yang J; Thompson P; Oliver J
    Clin Pharmacol Drug Dev; 2014 May; 3(3):170-8. PubMed ID: 27128606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS.
    Harris S; Tran JQ; Southworth H; Spencer CM; Cree BAC; Zamvil SS
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32737072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus.
    Taylor Meadows KR; Steinberg MW; Clemons B; Stokes ME; Opiteck GJ; Peach R; Scott FL
    PLoS One; 2018; 13(4):e0193236. PubMed ID: 29608575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.
    Scott FL; Clemons B; Brooks J; Brahmachary E; Powell R; Dedman H; Desale HG; Timony GA; Martinborough E; Rosen H; Roberts E; Boehm MF; Peach RJ
    Br J Pharmacol; 2016 Jun; 173(11):1778-92. PubMed ID: 26990079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects.
    Tran JQ; Zhang P; Walker S; Ghosh A; Syto M; Wang X; Harris S; Palmisano M
    Adv Ther; 2020 Dec; 37(12):4944-4958. PubMed ID: 33025342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Cohen JA; Comi G; Arnold DL; Bar-Or A; Selmaj KW; Steinman L; Havrdová EK; Cree BA; Montalbán X; Hartung HP; Huang V; Frohna P; Skolnick BE; Kappos L;
    Mult Scler; 2019 Aug; 25(9):1255-1262. PubMed ID: 30043658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
    Selkirk JV; Dines KC; Yan YG; Ching N; Dalvie D; Biswas S; Bortolato A; Schkeryantz JM; Lopez C; Ruiz I; Hargreaves R
    J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis.
    Rowan C; Ungaro R; Mehandru S; Colombel JF
    Expert Opin Pharmacother; 2022 Jun; 23(8):893-904. PubMed ID: 35503955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study.
    Tran JQ; Zhang P; Ghosh A; Liu L; Syto M; Wang X; Palmisano M
    Adv Ther; 2020 Oct; 37(10):4381-4395. PubMed ID: 32857315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults.
    Lee CA; Schreiber S; Bressler B; Adams JW; Oh DA; Tang YQ; Zhang J; Komori HK; Grundy JS
    Clin Pharmacol Drug Dev; 2024 May; 13(5):534-548. PubMed ID: 38345530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ozanimod for the treatment of relapsing remitting multiple sclerosis.
    Rasche L; Paul F
    Expert Opin Pharmacother; 2018 Dec; 19(18):2073-2086. PubMed ID: 30407868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety and pharmacokinetics of a novel, selective S1P1R modulator in healthy participants.
    Singhal S; Girgis IG; Xie J; Dutta S; Shevell DE; Throup J
    Expert Opin Investig Drugs; 2020 Apr; 29(4):411-422. PubMed ID: 32306792
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses.
    Armuzzi A; Cross RK; Lichtenstein GR; Hou J; Deepak P; Regueiro M; Wolf DC; Akukwe L; Ahmad HA; Jain A; Kozinn M; Wu H; Petersen A; Charles L; Long M
    Clin Gastroenterol Hepatol; 2024 May; 22(5):1067-1076.e3. PubMed ID: 38040274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.
    Swallow E; Patterson-Lomba O; Yin L; Mehta R; Pelletier C; Kao D; Sheffield JK; Stonehouse T; Signorovitch J
    J Comp Eff Res; 2020 Mar; 9(4):275-285. PubMed ID: 31948278
    [No Abstract]   [Full Text] [Related]  

  • 20. Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
    Choi D; Stewart AP; Bhat S
    Ann Pharmacother; 2022 May; 56(5):592-599. PubMed ID: 34423657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.